161 related articles for article (PubMed ID: 10344719)
1. Downregulated gelsolin expression in hyperplastic and neoplastic lesions of the prostate.
Lee HK; Driscoll D; Asch H; Asch B; Zhang PJ
Prostate; 1999 Jun; 40(1):14-9. PubMed ID: 10344719
[TBL] [Abstract][Full Text] [Related]
2. Decreased immunoexpression of prostate inhibin peptide in prostatic carcinoma: a study with monoclonal antibody.
Zhang PJ; Driscoll DL; Lee HK; Nolan C; Velagapudi SR
Hum Pathol; 1999 Feb; 30(2):168-72. PubMed ID: 10029444
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate.
Tamboli P; Amin MB; Xu HJ; Linden MD
Mod Pathol; 1998 Mar; 11(3):247-52. PubMed ID: 9521470
[TBL] [Abstract][Full Text] [Related]
4. The expression and localization of estrogen receptor beta in hyperplastic and neoplastic prostate lesions.
Levakov AF; Kaćanski MM; Vucković N; Zivojinov M; Amidzić J; Sabo JI
Vojnosanit Pregl; 2015 Oct; 72(10):906-13. PubMed ID: 26665557
[TBL] [Abstract][Full Text] [Related]
5. Cathepsin B in angiogenesis of human prostate: an immunohistochemical and immunoelectron microscopic analysis.
Sinha AA; Gleason DF; Staley NA; Wilson MJ; Sameni M; Sloane BF
Anat Rec; 1995 Mar; 241(3):353-62. PubMed ID: 7538734
[TBL] [Abstract][Full Text] [Related]
6. STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score.
Gomes IM; Arinto P; Lopes C; Santos CR; Maia CJ
Urol Oncol; 2014 Jan; 32(1):53.e23-9. PubMed ID: 24239460
[TBL] [Abstract][Full Text] [Related]
7. Localization of annexins I, II, IV and VII in whole prostate sections from radical prostatectomy patients.
Lehnigk U; Zimmermann U; Woenckhaus C; Giebel J
Histol Histopathol; 2005 Jul; 20(3):673-80. PubMed ID: 15944914
[TBL] [Abstract][Full Text] [Related]
8. Tenascin-C expression in prostatic intraepithelial neoplasia (PIN): a marker of progression?
Xue Y; Smedts F; Latijnhouwers MA; Ruijter ET; Aalders TW; de la Rosette JJ; Debruyne FM; Schalken JA
Anticancer Res; 1998; 18(4A):2679-84. PubMed ID: 9703928
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical profiles of claudin-3 in primary and metastatic prostatic adenocarcinoma.
Bartholow TL; Chandran UR; Becich MJ; Parwani AV
Diagn Pathol; 2011 Jan; 6():12. PubMed ID: 21255442
[TBL] [Abstract][Full Text] [Related]
10. Organ-wide telomeric status in diseased and disease-free prostatic tissues.
Heaphy CM; Fleet TM; Treat EG; Lee SJ; Smith AY; Davis MS; Griffith JK; Fischer EG; Bisoffi M
Prostate; 2010 Sep; 70(13):1471-9. PubMed ID: 20687220
[TBL] [Abstract][Full Text] [Related]
11. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
[TBL] [Abstract][Full Text] [Related]
12. A unifying hypothesis that links benign prostatic hyperplasia and prostatic intraepithelial neoplasia with prostate cancer. Invited comments.
Harvey H
Pathol Res Pract; 1995 Sep; 191(9):924-34. PubMed ID: 8606875
[TBL] [Abstract][Full Text] [Related]
13. Production of serum-free and total prostate-specific antigen due to prostatic intraepithelial neoplasia.
Minardi D; Galosi AB; Dell'Atti L; Hanitzsch H; Mario P; Muzzonigro G
Scand J Urol Nephrol; 2002; 36(5):323-9. PubMed ID: 12487735
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of high-grade prostatic intraepithelial neoplasia in transurethral resection specimens.
Pacelli A; Bostwick DG
Urology; 1997 Sep; 50(3):355-9. PubMed ID: 9301697
[TBL] [Abstract][Full Text] [Related]
15. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions.
Henrique R; Jerónimo C; Hoque MO; Carvalho AL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
DNA Cell Biol; 2005 Apr; 24(4):264-9. PubMed ID: 15812243
[TBL] [Abstract][Full Text] [Related]
16. Co-Expression of Putative Cancer Stem Cell Markers CD44 and CD133 in Prostate Carcinomas.
Kalantari E; Asgari M; Nikpanah S; Salarieh N; Asadi Lari MH; Madjd Z
Pathol Oncol Res; 2017 Oct; 23(4):793-802. PubMed ID: 28083789
[TBL] [Abstract][Full Text] [Related]
17. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases.
Bostwick DG; Pacelli A; Blute M; Roche P; Murphy GP
Cancer; 1998 Jun; 82(11):2256-61. PubMed ID: 9610707
[TBL] [Abstract][Full Text] [Related]
18. Role of androgen receptor in prostatic neoplasia versus hyperplasia.
Husain I; Shukla S; Soni P; Husain N
J Cancer Res Ther; 2016; 12(1):112-6. PubMed ID: 27072221
[TBL] [Abstract][Full Text] [Related]
19. Cell proliferation, apoptosis, oncogene, and tumor suppressor gene status in adenosis with comparison to benign prostatic hyperplasia, prostatic intraepithelial neoplasia, and cancer.
Häussler O; Epstein JI; Amin MB; Heitz PU; Hailemariam S
Hum Pathol; 1999 Sep; 30(9):1077-86. PubMed ID: 10492043
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer antigen-1 as a potential novel marker for prostate cancer.
Liu BQ; Wu YD; Li PH; Wei JX; Zhang T; Liu RL
Asian J Androl; 2007 Nov; 9(6):821-6. PubMed ID: 17968469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
